ApoGen Biotechnologies Raises $7M in Series A Funding

| December 13, 2016

article image
ApoGen Biotechnologies, Inc., a Seattle, WA-based biotechnology company focused on the development of a new class of therapeutics targeting drivers of cancer genomic mutation, raised $7m in Series A financing. Backers included Accelerator Corporation, AbbVie Ventures, Alexandria Venture Investments, ARCH Venture Partners, Eli Lilly and Company, Johnson & Johnson Innovation – JJDC, Inc., Watson Fund, L.P., WRF Capital and WuXi PharmaTech. The company intends to use the funds to develop highly selective and potent small molecule inhibitors that aim to slow or stop cancer mutation and the development of drug resistance as well as companion diagnostics to identify the patients likely to get the most benefit from these therapies.

Spotlight

PCPI

PCPI® is a membership organization uniquely focused on improving health outcomes through the advancement of performance measurement, clinical registries and quality improvement initiatives. Since 2000, PCPI has been a leader in convening experts to develop performance measures that improve the quality of healthcare for stakeholders across all of healthcare. We have a proven commitment to quality and have developed over 300 performance measures, 90 endorsed by NQF.

OTHER ARTICLES

Wisconsin biotech companies could play key roles in long-term economic recovery from COVID-19 pandemic

Article | April 19, 2020

Whether it’s called a modern “Manhattan Project” or a medical moon shot, the concept of long-term economic recovery rests on how confident people are they won’t risk serious illness by venturing forth in public again. Wisconsin stands to be a significant part of such an undertaking, whatever it’s called. The shorter-term debate is well under way over the gradual lifting of COVID-19 emergency rules, such as the now-extended “safer-at-home” order in Wisconsin. At least a dozen states, including regional coalitions on the East and West coasts, are exploring next steps as they seek to balance responses to the virus with calls for reopening the economy, at least, in part. Wisconsin’s ability to shape longer-term responses will come from private and public resources, which range from companies engaged in production of diagnostics.

Read More

2 Small-Cap Biotech Stocks You Haven't Heard of, But Should Know About

Article | April 17, 2020

With everything that's going on with the COVID-19 pandemic, many healthcare companies have grabbed plenty of spotlight during these challenging times. At the same time, a number of otherwise promising businesses have slipped under the radar. That's especially true for small-cap biotech stocks that aren't actively involved in developing tests, vaccines or treatments for COVID-19. Vaccine developers, protective equipment producers, and healthcare service providers are all attracting plenty of attention during this pandemic, but there are just as many promising biotech stocks that aren't involved in these areas. Here are two such companies that you might have missed, but they deserve a spot on your watch list.

Read More

Top 10 biotech IPOs in 2019

Article | February 24, 2020

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More

Translating Pharmacomicrobiomics: Three Actionable Challenges/Prospects in 2020

Article | February 24, 2020

The year 2020 marks a decade since the term pharmacomicrobiomics was coined (Rizkallah et al., 2010) to crystallize a century-old concept of mutual interactions between humans, drugs, and the microbial world. The human microbiome, with its immense metabolic potential that exceeds and expands the human metabolic capacities, has the ability to modulate pharmacotherapy by affecting both pharmacokinetics and pharmacodynamics of drug molecules:

Read More

Spotlight

PCPI

PCPI® is a membership organization uniquely focused on improving health outcomes through the advancement of performance measurement, clinical registries and quality improvement initiatives. Since 2000, PCPI has been a leader in convening experts to develop performance measures that improve the quality of healthcare for stakeholders across all of healthcare. We have a proven commitment to quality and have developed over 300 performance measures, 90 endorsed by NQF.

Events